AIM：To investigate the predictive factors for shortterm effects of intravitreal bevacizumab injections on central subfield foveal thickness（CSFT）in patients with macular edema（ME）secondary to central retinal vein...AIM：To investigate the predictive factors for shortterm effects of intravitreal bevacizumab injections on central subfield foveal thickness（CSFT）in patients with macular edema（ME）secondary to central retinal vein occlusion（CRVO）.·METHODS：This was a retrospective study in 60 eyes treated with intravitreal bevacizumab injections for ME due to CRVO.Follow-up was three months.The Early Treatment Diabetic Retinopathy Study（ETDRS）score and CSFT measured by spectral-domain optical coherence tomography（SD-OCT）were used to observe the changes in best-corrected visual acuity（BCVA）.Baseline BCVA,CSFT,age,CRVO duration and the presence of cystoid macular edema（CME）or subretinal fluid（SRF）were analyzed as potential predictive factors of the effects of intravitreal bevacizumab injections.·R ESULTS：BCVA improved from 0.9 log MAR at baseline to 0.6 log MAR at 3mo,which was associated with a significant reduction in CSFT from 721μm to 392μm 3mo after injection.About 50%of CME cases and more than90%of SRF cases responded to treatment with a complete resolution at 3mo.Age（=0.036）and low baseline CSFT（=0.037）were associated with a good 3-month prognosis.Patients〉60 years old achieved better CME resolution（=0.031）and lower CSFT at 3mo（305μm 474μm,=0.003）.·CONCLUSION：Intravitreal bevacizumab significantly improved visual acuity and CSFT in patients with CRVO after 3mo.Older age and lower baseline CSFT were good predictors of short-term CSFT outcomes.The retinal thickness response to bevacizumab might depend on the resolution of CME rather than SRF.展开更多
·AIM:To compare the efficacy and safety of intravitreal aflibercept with dexamethasone implant in the treatment of macular edema(ME)associated with diabetic retinopathy(DR)or retinal vein occlusion(RVO).·MET...·AIM:To compare the efficacy and safety of intravitreal aflibercept with dexamethasone implant in the treatment of macular edema(ME)associated with diabetic retinopathy(DR)or retinal vein occlusion(RVO).·METHODS:A comprehensive search of studies comparing dexamethasone and aflibercept in patients with ME was conducted at PubMed,Embase,and Cochrane Central Register of Controlled Trials from the beginning of library to April 16,2021.Extracting the data including bestcorrected visual acuity(BCVA),central retinal thickness(CRT),number of injections and serious adverse events(SAEs)from the final qualified articles.RevMan 5.3 software was used for Meta-analysis of the included studies.·RESULTS:Totally 7 studies with 369 eyes were included.The causes of ME in the final screening study included RVO and DR.Compared with the aflibercept treatment group,the BCVA of the dexamethasone implant treatment group showed no significant difference in the follow-up for 3 mo[mean difference(MD):-0.05,95%confidence interval(CI):-0.11,0.02;P=0.17]and 12 mo(MD:-0.01,95%CI:-0.38,0.37;P=0.98),but it was slightly worse than the aflibercept group at 6 mo(MD:0.12.95%CI:0.03,0.21;P=0.008).In terms of CRT reduction,there was no significant difference between the two groups at 3 mo(MD:-28.14,95%CI:-79.95,23.67;P=0.29),6 mo(MD:27.67,95%CI:-84.89,140.24;P=0.63),and 12 mo(MD:-59.00,95%CI:-127.37,9.37;P=0.09).However,dexamethasone implant had fewer injections,but more adverse events such as elevated intraocular pressure(IOP)and cataract.·CONCLUSION:Intravitreal injection of aflibercept and dexamethasone implant can both effectively increase BCVA and reduce CRT.Compared with aflibercept,dexamethasone implant is not inferior in improving vision and reducing CRT in the initial treatment period(3 mo)and long-term treatment period(12 mo).Besides,it has fewer injections and more likely to cause elevated IOP and cataract.展开更多
The role of catecholamine (CA) in the pathogenesis and development of macular edema of central serous chorioretinopathy (CSC) was studied, and its relations with visual acuity were investigated Plasma concentrations...The role of catecholamine (CA) in the pathogenesis and development of macular edema of central serous chorioretinopathy (CSC) was studied, and its relations with visual acuity were investigated Plasma concentrations of epinephrine (E) and norepinephrine (NE) were determined in 30 consecutive eyes with CSC Central macular thickness analysis was done by RTA and all the data were compared with normal eyes and analyzed with SAS software package Plasma concentrations of E and NE were increased to (569±123) ng/L and (721±104) ng/L respectively in active CSC patients, significantly higher than those in normal subjects ( P< 0 01), and decreased to normal in convalescent stage RTA analysis revealed that the retinal thickness of CSC patients was increased at active and recovery stage as compared with normal subjects; and the plasma concentration of E was significantly correlated with central macular thickness( t =2 173, P< 0 05) Also, central macular thickness measured by RTA was significantly correlated with the visual acuity ( r = -0 8046 , P< 0 001) in CSC eyes RTA analysis might be useful to quantitatively detect and evaluate prognosis in CSC patients The plasma concentration of E, which was highly correlated with macular edema, might play an important role in the early damage and the pathogenesis of CSC展开更多
目的:探讨OCTA检查在视网膜静脉阻塞诊疗中的重要应用价值。方法:采用回顾性病例对照研究,选取2018-01/10于大连市第三人民医院眼科门诊确诊为视网膜静脉阻塞的患者38例38眼,其患病眼为A组,对侧健康眼为B组。所有患者均接受OCTA对黄斑...目的:探讨OCTA检查在视网膜静脉阻塞诊疗中的重要应用价值。方法:采用回顾性病例对照研究,选取2018-01/10于大连市第三人民医院眼科门诊确诊为视网膜静脉阻塞的患者38例38眼,其患病眼为A组,对侧健康眼为B组。所有患者均接受OCTA对黄斑区视网膜行3mm×3mm范围的模式扫描,获得表层视网膜、深层视网膜、外层视网膜及脉络膜毛细血管层4个层面黄斑血流密度图,测量表层视网膜中心凹无血管区面积(FAZ),Image J软件计算4个层面黄斑区血流密度(MVD),OCT模式测量黄斑中心凹的水平厚度与垂直厚度(CFT)。结果: A组和B组浅层视网膜FAZ、水平CFT及垂直CFT测量均有差异( P <0.01)。A组和B组表层视网膜及深层视网MVD均有差异( P <0.01),外层视网膜层MVD、脉络膜毛细血管层MVD结果无差异( P =0.542、0.489)。BCVA(LogMAR)分别与表层视网膜FAZ、水平CFT及垂直CFT呈正相关( r =0.482、0.652、0.621,均 P <0.01),与表层视网膜MVD及深层视网膜MVD呈负相关( r =-0.486 、-0.465,均 P <0.01)。结论:应用OCTA检查对提示视网膜静脉阻塞患者黄斑区视网膜的微循环障碍和视力预后有重要指导意义。展开更多
文摘AIM：To investigate the predictive factors for shortterm effects of intravitreal bevacizumab injections on central subfield foveal thickness（CSFT）in patients with macular edema（ME）secondary to central retinal vein occlusion（CRVO）.·METHODS：This was a retrospective study in 60 eyes treated with intravitreal bevacizumab injections for ME due to CRVO.Follow-up was three months.The Early Treatment Diabetic Retinopathy Study（ETDRS）score and CSFT measured by spectral-domain optical coherence tomography（SD-OCT）were used to observe the changes in best-corrected visual acuity（BCVA）.Baseline BCVA,CSFT,age,CRVO duration and the presence of cystoid macular edema（CME）or subretinal fluid（SRF）were analyzed as potential predictive factors of the effects of intravitreal bevacizumab injections.·R ESULTS：BCVA improved from 0.9 log MAR at baseline to 0.6 log MAR at 3mo,which was associated with a significant reduction in CSFT from 721μm to 392μm 3mo after injection.About 50%of CME cases and more than90%of SRF cases responded to treatment with a complete resolution at 3mo.Age（=0.036）and low baseline CSFT（=0.037）were associated with a good 3-month prognosis.Patients〉60 years old achieved better CME resolution（=0.031）and lower CSFT at 3mo（305μm 474μm,=0.003）.·CONCLUSION：Intravitreal bevacizumab significantly improved visual acuity and CSFT in patients with CRVO after 3mo.Older age and lower baseline CSFT were good predictors of short-term CSFT outcomes.The retinal thickness response to bevacizumab might depend on the resolution of CME rather than SRF.
基金Supported by Key Research and Development Program of Shaanxi Province(No.2021SF-155)Natural Science Foundation of Jiangxi Province(No.20192BAB205049)+1 种基金National Innovation and Entrepreneurship Training Program for College Students(No.X202110698092)Clinical Research Grant from First Affiliated Hospital of Xi’an Jiaotong University(No.20ZD02)。
文摘·AIM:To compare the efficacy and safety of intravitreal aflibercept with dexamethasone implant in the treatment of macular edema(ME)associated with diabetic retinopathy(DR)or retinal vein occlusion(RVO).·METHODS:A comprehensive search of studies comparing dexamethasone and aflibercept in patients with ME was conducted at PubMed,Embase,and Cochrane Central Register of Controlled Trials from the beginning of library to April 16,2021.Extracting the data including bestcorrected visual acuity(BCVA),central retinal thickness(CRT),number of injections and serious adverse events(SAEs)from the final qualified articles.RevMan 5.3 software was used for Meta-analysis of the included studies.·RESULTS:Totally 7 studies with 369 eyes were included.The causes of ME in the final screening study included RVO and DR.Compared with the aflibercept treatment group,the BCVA of the dexamethasone implant treatment group showed no significant difference in the follow-up for 3 mo[mean difference(MD):-0.05,95%confidence interval(CI):-0.11,0.02;P=0.17]and 12 mo(MD:-0.01,95%CI:-0.38,0.37;P=0.98),but it was slightly worse than the aflibercept group at 6 mo(MD:0.12.95%CI:0.03,0.21;P=0.008).In terms of CRT reduction,there was no significant difference between the two groups at 3 mo(MD:-28.14,95%CI:-79.95,23.67;P=0.29),6 mo(MD:27.67,95%CI:-84.89,140.24;P=0.63),and 12 mo(MD:-59.00,95%CI:-127.37,9.37;P=0.09).However,dexamethasone implant had fewer injections,but more adverse events such as elevated intraocular pressure(IOP)and cataract.·CONCLUSION:Intravitreal injection of aflibercept and dexamethasone implant can both effectively increase BCVA and reduce CRT.Compared with aflibercept,dexamethasone implant is not inferior in improving vision and reducing CRT in the initial treatment period(3 mo)and long-term treatment period(12 mo).Besides,it has fewer injections and more likely to cause elevated IOP and cataract.
基金ThisprojectwassupportedbyHubeiScienceDevelopmentalFoundation (No 2 0 0 0 2P170 5 )
文摘The role of catecholamine (CA) in the pathogenesis and development of macular edema of central serous chorioretinopathy (CSC) was studied, and its relations with visual acuity were investigated Plasma concentrations of epinephrine (E) and norepinephrine (NE) were determined in 30 consecutive eyes with CSC Central macular thickness analysis was done by RTA and all the data were compared with normal eyes and analyzed with SAS software package Plasma concentrations of E and NE were increased to (569±123) ng/L and (721±104) ng/L respectively in active CSC patients, significantly higher than those in normal subjects ( P< 0 01), and decreased to normal in convalescent stage RTA analysis revealed that the retinal thickness of CSC patients was increased at active and recovery stage as compared with normal subjects; and the plasma concentration of E was significantly correlated with central macular thickness( t =2 173, P< 0 05) Also, central macular thickness measured by RTA was significantly correlated with the visual acuity ( r = -0 8046 , P< 0 001) in CSC eyes RTA analysis might be useful to quantitatively detect and evaluate prognosis in CSC patients The plasma concentration of E, which was highly correlated with macular edema, might play an important role in the early damage and the pathogenesis of CSC
文摘目的:探讨OCTA检查在视网膜静脉阻塞诊疗中的重要应用价值。方法:采用回顾性病例对照研究,选取2018-01/10于大连市第三人民医院眼科门诊确诊为视网膜静脉阻塞的患者38例38眼,其患病眼为A组,对侧健康眼为B组。所有患者均接受OCTA对黄斑区视网膜行3mm×3mm范围的模式扫描,获得表层视网膜、深层视网膜、外层视网膜及脉络膜毛细血管层4个层面黄斑血流密度图,测量表层视网膜中心凹无血管区面积(FAZ),Image J软件计算4个层面黄斑区血流密度(MVD),OCT模式测量黄斑中心凹的水平厚度与垂直厚度(CFT)。结果: A组和B组浅层视网膜FAZ、水平CFT及垂直CFT测量均有差异( P <0.01)。A组和B组表层视网膜及深层视网MVD均有差异( P <0.01),外层视网膜层MVD、脉络膜毛细血管层MVD结果无差异( P =0.542、0.489)。BCVA(LogMAR)分别与表层视网膜FAZ、水平CFT及垂直CFT呈正相关( r =0.482、0.652、0.621,均 P <0.01),与表层视网膜MVD及深层视网膜MVD呈负相关( r =-0.486 、-0.465,均 P <0.01)。结论:应用OCTA检查对提示视网膜静脉阻塞患者黄斑区视网膜的微循环障碍和视力预后有重要指导意义。
